» Articles » PMID: 39312178

Harnessing the Benefits of Physical Exercise-induced Melatonin: a Potential Promising Approach to Combat Alzheimer's Disease by Targeting Beta-amyloid (Aβ)

Overview
Specialty Endocrinology
Date 2024 Sep 23
PMID 39312178
Authors
Affiliations
Soon will be listed here.
Abstract

Alzheimer's disease (AD) is a chronic neurogenerative disease that impairs cognition, learning, behavior, and memory. The aberrant accumulation of extracellular amyloid-β (Aβ) plaques is a characteristic of AD. It has been demonstrated that melatonin exerts a significant role in AD prevention and treatment via its antioxidant effects, reducing neuroinflammation, and Aβ. Moreover, studies have shown that physical exercise (PE) is not only a promising non-pharmacological strategy for AD prevention and treatment but can also lead to an increase in melatonin levels. Hence, we hypothesized that PE can contribute to AD prevention and treatment by increasing melatonin levels and reducing Aβ accumulation, enhancing Aβ clearance, and modulating inflammation in these patients. However, the mechanisms by which PE increases melatonin synthesis and the cellular and molecular mechanisms of actions of melatonin in AD prevention and treatment have not to date been completely understood. Therefore, in the future, further investigations are required to elucidate the underlying mechanisms, optimize intervention strategies, identify biomarkers, and validate findings through clinical trials. Understanding the potential of exercise-induced melatonin in AD holds promise for innovative therapeutic interventions and future directions in AD research.

Citing Articles

Melatonin from Plants: Going Beyond Traditional Central Nervous System Targeting-A Comprehensive Review of Its Unusual Health Benefits.

Fornari Laurindo L, Simili O, Cressoni Araujo A, Landgraf Guiguer E, Direito R, Valenti V Biology (Basel). 2025; 14(2).

PMID: 40001911 PMC: 11851571. DOI: 10.3390/biology14020143.

References
1.
Mustapic M, Hadzija M, Pavlovic M, Pavkovic P, Presecki P, Mrazovac D . Alzheimer's disease and type 2 diabetes: the association study of polymorphisms in tumor necrosis factor-alpha and apolipoprotein E genes. Metab Brain Dis. 2012; 27(4):507-12. DOI: 10.1007/s11011-012-9310-1. View

2.
Leszek J, Sochocka M, Gasiorowski K . Vascular factors and epigenetic modifications in the pathogenesis of Alzheimer's disease. J Neurol Sci. 2012; 323(1-2):25-32. DOI: 10.1016/j.jns.2012.09.010. View

3.
Rocchi A, Valensin D, Aldinucci C, Giani G, Barbucci R, Gaggelli E . NMR metabolomic investigation of astrocytes interacted with Aβ₄₂ or its complexes with either copper(II) or zinc(II). J Inorg Biochem. 2012; 117:326-33. DOI: 10.1016/j.jinorgbio.2012.08.021. View

4.
Sultana R, Butterfield D . Role of oxidative stress in the progression of Alzheimer's disease. J Alzheimers Dis. 2010; 19(1):341-53. DOI: 10.3233/JAD-2010-1222. View

5.
Lourida I, Hannon E, Littlejohns T, Langa K, Hypponen E, Kuzma E . Association of Lifestyle and Genetic Risk With Incidence of Dementia. JAMA. 2019; 322(5):430-437. PMC: 6628594. DOI: 10.1001/jama.2019.9879. View